Abbisko Therapeutics Co. Ltd. announced that it has received $123 million in a round of funding co-led by new investors The Carlyle Group Inc. (NasdaqGS:CG), Warburg Pincus LLC, OrbiMed Advisors LLC, Lake Bleu Capital (Hong Kong) Limited, and a Boston-based investor on January 8, 2021. The transaction also included participation from new investors Janchor Partners Ltd., Greater Bay Area Homeland Development Fund, a fund managed by Greater Bay Area Homeland Investments Limited, Sage Partners, SHC, and another strategic investor, along with existing investors CICC Capital Management Co., Ltd., Hankang Capital Management Limited, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Lilly Asia Ventures, and Temasek Holdings (Private) Limited.

The company has raised $263 million in funding till date.